US pharmaceutical company Pfizer and Germany’s BioNTech said they were on track to apply for regulatory approval of their BNT162b2gi Covid vaccine next October. Pfizer explained in a statement that if authorization or regulatory approval is obtained, they plan to supply up to 100 million doses worldwide by the end of 2020 and about 1.3 billion doses by the end of 2021.
–
Phase 2
The two companies have initiated Phase 2 of 3 of the vaccine testing globally to evaluate its effectiveness. In the first phase (at the second dose in progress) 11,000 people between the USA and Germany were involved and the results are encouraging: the vaccine was well tolerated. In the second, 30,000 people aged between 18 and 85 are expected to participate in the United States, Argentina, Brazil, Germany, Turkey and South Africa.
Aiming to launch the vaccine in October, US futures took a leap overnight. The time line of the two companies would make the vaccine one of the fastest in the world. Some analysts expect it to be approved in the United States as early as November in order to be able to enter the market immediately, a move that could work in favor of the current President Trump for the next elections.
–
The aziede
Pfizer was born in 1849, in New York, by two German immigrants, cousins Charles Pfizer and Charles Erhart who began to produce raw materials for the chemical and food sector obtained thanks to fermentation processes. He subsequently became a producer of tartaric acid, citric acid, vitamin C and was able to mass produce penicillin of which he became a global producer. After more than 150 years of history, it develops, produces and markets vaccines and drugs, for the treatment and prevention of diseases, both the most common and the rare ones.
BioNTech a German biotechnology company dedicated to the development and production of active immunotherapies. Founded in 2008, it combines innovative research with cutting-edge technologies to develop pioneering therapies for cancer and more.
– .
